|
|
Post by obamayoumama on Mar 29, 2016 11:42:31 GMT -5
At the first of 2016 Jay had a sell rating on MNKD with a $1.00 target. On December 31, 2015 MNKD closed at $1.45. On Jan. 19th, 2016 he lowered his PT to $.25 on MNKD. Jay Olson follows only one other stock, PTLA. On December 31, 2015 he had a buy rating on PTLA and a $65.00 price target. On 12/31/2015 PTLA closed at $51.45. So if an investor or hedge fund bought PTLA and shorted MNKD using the 12/31/2015 prices, how are Jay's recommendations doing this year? PTLA made a multi year low yesterday at $18.20 and closed at $19.00. On Sunday Jay removed his buy on PTLA and placed it with a neutral and a $30.00 price target. So let's do the math on our analyst Jay Olson as of last night. If you had invested $50k in PTLA on Dec. 31, 2015 it would be worth $18,464.52. Your $50k in MNKD that you shorted on December 31, 2015 @ $1.45 would be worth $43,793.10. You would now have and account balance of $62,257.62 not including the HTB interest on your MNKD stock. If PTLA stays here and MNKD goes over $3.00, your entire investment is gone after paying the interest, or over $3.43 not including the interest. It gets better! While Jay was suggesting that clients Short or Sell MNKD, Goldman Sachs was buying, see the latest institutional holdings. What was GS doing with their PTLA holdings that Jay had a buy? GS was selling of course, see the latest on PTLA institutional holdings. I believe Jay has a middle name, drum roll please........Jay Patsy Olson!
|
|
|
|
Post by bradleysbest on Mar 29, 2016 12:57:15 GMT -5
You should email that directly to Jay & GS!
|
|
|
|
Post by obamayoumama on Mar 29, 2016 15:09:45 GMT -5
At the first of 2016 Jay had a sell rating on MNKD with a $1.00 target. On December 31, 2015 MNKD closed at $1.45. On Jan. 19th, 2016 he lowered his PT to $.25 on MNKD. Jay Olson follows only one other stock, PTLA. On December 31, 2015 he had a buy rating on PTLA and a $65.00 price target. On 12/31/2015 PTLA closed at $51.45. So if an investor or hedge fund bought PTLA and shorted MNKD using the 12/31/2015 prices, how are Jay's recommendations doing this year? PTLA made a multi year low yesterday at $18.20 and closed at $19.00. On Sunday Jay removed his buy on PTLA and placed it with a neutral and a $30.00 price target. So let's do the math on our analyst Jay Olson as of last night. If you had invested $50k in PTLA on Dec. 31, 2015 it would be worth $18,464.52. Your $50k in MNKD that you shorted on December 31, 2015 @ $1.45 would be worth $43,793.10. You would now have and account balance of $62,257.62 not including the HTB interest on your MNKD stock. If PTLA stays here and MNKD goes over $3.00, your entire investment is gone after paying the interest, or over $3.43 not including the interest. It gets better! While Jay was suggesting that clients Short or Sell MNKD, Goldman Sachs was buying, see the latest institutional holdings. What was GS doing with their PTLA holdings that Jay had a buy? GS was selling of course, see the latest on PTLA institutional holdings. I believe Jay has a middle name, drum roll please........Jay Patsy Olson! Update: The Jay "Patsy" Olson portfolio is down 40.5% this year plus interest as of the close today. |
|
|
|
Post by babaoriley on Mar 29, 2016 15:14:56 GMT -5
Can't make this stuff up! Absolutely stunning, and this is the tank in which we swim.
|
|
|
|
Post by bioexec25 on Mar 29, 2016 15:28:30 GMT -5
Jeez louise what a vivid example Mr Obamayoumama (feels good typing that). P
Perhaps Jay gets more than enough of a bonus for driving down the pps for the other side of the house to gobble up cheap shares. What a POS.
|
|
|
|
Post by brotherm1 on Mar 29, 2016 18:27:08 GMT -5
Regarding Jay's sell recommendation on MNKD while Goldman was buying, is that not front running and illegal? Or am I not understanding clearly?
|
|
|
|
Post by peppy on Mar 29, 2016 18:32:10 GMT -5
Regarding Jay's sell recommendation on MNKD while Goldman was buying, is that not front running and illegal? Or am I not understanding clearly? remember the great recession? GS selling the collateralized debt obligations to clients, and shorted them through AIG at the same time. and then received millions in the bail out. GS is the federal reserves trading arm. It seems they can do what ever they want.
|
|
|
|
Post by dreamboatcruise on Mar 29, 2016 20:58:45 GMT -5
Regarding Jay's sell recommendation on MNKD while Goldman was buying, is that not front running and illegal? Or am I not understanding clearly? Legally it would seem the same as if I were writing glowing articles (or posts here) about Afrezza and MNKD while I was silently lightening my position through sales of shares. In general there is no law against spinning in one direction while taking the opposite side of the trade. |
|
|
|
Post by robsacher on Mar 29, 2016 22:02:44 GMT -5
At the first of 2016 Jay had a sell rating on MNKD with a $1.00 target. On December 31, 2015 MNKD closed at $1.45. On Jan. 19th, 2016 he lowered his PT to $.25 on MNKD. Jay Olson follows only one other stock, PTLA. On December 31, 2015 he had a buy rating on PTLA and a $65.00 price target. On 12/31/2015 PTLA closed at $51.45. So if an investor or hedge fund bought PTLA and shorted MNKD using the 12/31/2015 prices, how are Jay's recommendations doing this year? PTLA made a multi year low yesterday at $18.20 and closed at $19.00. On Sunday Jay removed his buy on PTLA and placed it with a neutral and a $30.00 price target. So let's do the math on our analyst Jay Olson as of last night. If you had invested $50k in PTLA on Dec. 31, 2015 it would be worth $18,464.52. Your $50k in MNKD that you shorted on December 31, 2015 @ $1.45 would be worth $43,793.10. You would now have and account balance of $62,257.62 not including the HTB interest on your MNKD stock. If PTLA stays here and MNKD goes over $3.00, your entire investment is gone after paying the interest, or over $3.43 not including the interest. It gets better! While Jay was suggesting that clients Short or Sell MNKD, Goldman Sachs was buying, see the latest institutional holdings. What was GS doing with their PTLA holdings that Jay had a buy? GS was selling of course, see the latest on PTLA institutional holdings. I believe Jay has a middle name, drum roll please........Jay Patsy Olson! Thank you for your analysis. Everyone should share your findings and repost on the SA articles... |
|
|
|
Post by avogadro on Mar 30, 2016 8:12:57 GMT -5
How did this little piece of sheet, MNKD, gather such powerful enemies, and so MANY of them!!
|
|
|
|
Post by mindovermatter on Mar 30, 2016 8:19:45 GMT -5
How did this little piece of sheet, MNKD, gather such powerful enemies, and so MANY of them!! Can't say for sure but I think it all took shape back in '07 when Exubera failed and all the other inhaled insulin companies shuttered their projects sans Mannkind. Mannkind became a viable short target. Wall St saw Al as the biotech Don Quixote going after an impossible windmill of a market that didn't exist. To date, they have been right. Inahled insulin has no market. |
|
|
|
Post by avogadro on Mar 30, 2016 9:14:58 GMT -5
How did this little piece of sheet, MNKD, gather such powerful enemies, and so MANY of them!! Can't say for sure but I think it all took shape back in '07 when Exubera failed and all the other inhaled insulin companies shuttered their projects sans Mannkind. Mannkind became a viable short target. Wall St saw Al as the biotech Don Quixote going after an impossible windmill of a market that didn't exist. To date, they have been right. Inahled insulin has no market. True, but this is largely due to the treacherous actions of SNY supported by GS, the FDA, the Insurance industry, dozens of SA articles, the Gutter.com, M.F., and by the ALMOST suicidal behavior of MNKD management. |
|
|
|
Post by wmdhunt on Mar 30, 2016 9:15:00 GMT -5
Several of us filed complaints on this with the SEC. Of course, no action nor acknowledgments. I hate Goldman and don't know how the gov't continues to ignore their crap except for a hand slap now and then.
|
|
|
|
Post by kbrion77 on Mar 30, 2016 9:18:15 GMT -5
How did this little piece of sheet, MNKD, gather such powerful enemies, and so MANY of them!! Can't say for sure but I think it all took shape back in '07 when Exubera failed and all the other inhaled insulin companies shuttered their projects sans Mannkind. Mannkind became a viable short target. Wall St saw Al as the biotech Don Quixote going after an impossible windmill of a market that didn't exist. To date, they have been right. Inahled insulin has no market. “There’s no chance that the iPhone is going to get any significant market share. No chance. It’s a $500 subsidized item.” -Steve Ballmer |
|
|
|
Post by mindovermatter on Mar 30, 2016 9:26:55 GMT -5
Can't say for sure but I think it all took shape back in '07 when Exubera failed and all the other inhaled insulin companies shuttered their projects sans Mannkind. Mannkind became a viable short target. Wall St saw Al as the biotech Don Quixote going after an impossible windmill of a market that didn't exist. To date, they have been right. Inahled insulin has no market. “There’s no chance that the iPhone is going to get any significant market share. No chance. It’s a $500 subsidized item.” -Steve Ballmer drugs that depend on others to prescribe and health insurance to cover it are vastly different than an electrical gadget from a company that was already doing well with other products, had support from Wall Street and had an already wide cult following. These silly comparisons are a non starter. I'll say you have a point if Afrezza actually catches on. Has it caught on after a year? No. Afrezza is a bust so far. |
|
